Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues
Clinical and Molecular Hepatology · 01.07.2025 · 31 (3) · 1003-1017
DOI: 10.3350/cmh.2024.1070 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2025. Verfasst von Rui Huang und 51 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Metabolic Syndrome, Antiviral Agents, Nucleosides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Ministry of Education.
Abstract (Originalsprache)
Background/Aims: Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods
We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results
The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
- Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, China.
- Department of Internal Medicine, Hanyang University, College of Medicine, Seoul, Korea.
- Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
- Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Förderung
- Center of Excellence for Metabolic Associated Fatty Liver Disease
- National Sun Yat-sen University
- Ministry of Education
Zitieren
APA
Huang, R., Jun, D. W., Toyoda, H., Hsu, Y. C., Trinh, H., Nozaki, A., Ishikawa, T., Watanabe, T., Uojima, H., Huang, D. Q., Honda, T., Tanaka, Y., Vutien, P., Marciano, S., Abe, H., Enomoto, M., Atsukawa, M., Takahashi, H., Tsuji, K., …, & Nguyen, M. H. (2025). Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues. Clinical and Molecular Hepatology, 31(3), 1003-1017. https://doi.org/10.3350/cmh.2024.1070
Vancouver
Huang R, Jun DW, Toyoda H, Hsu YC, Trinh H, Nozaki A, et al. Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues. Clinical and Molecular Hepatology. 2025;31(3):1003-1017. doi:10.3350/cmh.2024.1070
BibTeX
@article{Huang2025,
author = {Huang, Rui and Jun, Dae Won and Toyoda, Hidenori and Hsu, Yao-Chun and Trinh, Huy and Nozaki, Akito and Ishikawa, Toru and Watanabe, Tsunamasa and Uojima, Haruki and Huang, Daniel Q and Honda, Takashi and Tanaka, Yasuhito and Vutien, Philip and Marciano, Sebastián and Abe, Hiroshi and Enomoto, Masaru and Atsukawa, Masanori and Takahashi, Hirokazu and Tsuji, Kunihiko and Takaguchi, Koichi and Tsai, Pei-Chien and Dai, Chia-Yen and Huang, Jee-Fu and Huang, Chung-Feng and Yeh, Ming-Lun and Yoon, Eileen and Kim, Sung Eun and Ahn, Sang Bong and Kim, Gi-Ae and Jung, Jang Han and Jeong, Soung Won and Oh, Hyunwoo and Tseng, Cheng-Hao and Ishigami, Masatoshi and Chau, Angela and Maeda, Mayumi and Yasuda, Satoshi and Chuma, Makoto and Ito, Takanori and Kawashima, Keigo and Liu, Joanne Kimiko and Gadano, Adrian and Kozuka, Ritsuzo and Itokawa, Norio and Inoue, Kaori and Senoh, Tomonori and Li, Jie and Chuang, Wan-Long and Cheung, Ramsey and Wu, Chao and Yu, Ming-Lung and Nguyen, Mindie H},
title = {Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues},
journal = {Clinical and Molecular Hepatology},
year = {2025},
volume = {31},
number = {3},
pages = {1003--1017},
doi = {10.3350/cmh.2024.1070}
}
EUVIMED